Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 19Sarcoma 4Gynecologic 4Gastrointestinal 4Thoracic 3Genitourinary 3Endocrine 3Breast 3NET 2Dermatologic 2CNS 2Other solid neoplasm 1Lymphoid 1

Conditions

Advanced Solid Tumor 30Mesothelioma 20Solid Tumor 18Mesothelioma, Malignant 18Advanced Solid Tumors 18Solid Tumors 16Solid Tumor, Adult 11Melanoma 10Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 8Colorectal Neoplasms 8Retinoblastoma 7Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Lung Neoplasms 6Cholangiocarcinoma 6Advanced Malignant Solid Neoplasm 6Triple Negative Breast Neoplasms 5Sarcoma 5Stomach Neoplasms 4Pancreatic Neoplasms 4Malignant Solid Neoplasm 4Esophageal Neoplasms 4Advanced or Metastatic Solid Tumors 4Small Cell Lung Carcinoma 3Neoplasms 3Malignant Solid Tumor 3Locally Advanced or Metastatic Solid Tumors 3Hematopoietic and Lymphatic System Neoplasm 3

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Salivary Gland Neoplasms × Other solid neoplasm × Clear all
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡